First AD

Second AD

Peter Riedell, MD, is an associate professor of medicine in the Section of Hematology/Oncology at the University of Chicago.

CAR T in CLL: Data Highlights and Long-Term Outcomes From ASH 2024

Video content above is prompted by the following:

There were recent data updates on the combination with liso-cel and ibrutinib from the TRANSCEND CLL-004 study at ASH 2024. 

 what were some of the data highlights, and has this data influenced your clinical practice?

In your clinical expertise, is CAR T potentially curative in R/R CLL?

In your opinion, what does the future look like for CAR T in R/R CLL?

Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL 

OncLive Insights

Experts discuss recent data updates from the TRANSCEND CLL-004 study on the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib, the potential curative role of chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and the future outlook for CAR T in treating R/R CLL.